Biotech Values

[genisi]

And a call for guideline changes:

This Medtronic-supported research is the first to show the significant lifesaving value of CRT-D for mildly symptomatic heart failure patients and builds upon the growing body of evidence calling for guideline changes,”

said Pat Mackin, president of the Cardiac Rhythm Disease Management business and senior vice president at Medtronic.